Genitourinary tumours, prostate

LBA24 

Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results of expanded cohort 6 of the COSMIC-021 Study

Agarwal, et al.

Conclusions

C + A demonstrated clinically meaningful activity with a manageable safety profile in mCRPC, supporting a phase 3 study of C + A versus second NHT (CONTACT-02; NCT04446117).

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA24.html.pdf

577O 

PRINCE: Interim Analysis of the Phase Ib Study of 177Lu-PSMA-617 in Combination with Pembrolizumab for Metastatic Castration Resistant Prostate Cancer (mCRPC)

S.K. Sandhu, et al.

Conclusions

The combination of Lu-PSMA-617 and pembrolizumab had promising activity. Toxicities were consistent with those of single agent Lu-PSMA-617 and pembrolizumab.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/577O.html.pdf

LBA25 

Final overall survival (OS) analysis from ARCHES: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

A.J. Armstrong, et al.

Conclusions

This final analysis demonstrates that ENZA + ADT significantly prolongs survival in men with mHSPC and, together with the acceptable safety profile, supports the clinical benefit of ENZA + ADT in men with mHSPC.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA25.html.pdf